GlobalData on MSN
Sound Pharmaceuticals concludes subject enrolment for SPI-1005 trial
The purpose of the trial is to collect additional safety data supporting chronic daily dosing of SPI-1005.
MCCLELLAN PARK, CA / ACCESSWIRE / January 9, 2023 / SPI Energy Co., Ltd., (NASDAQ:SPI) (the "Company"), a global renewable energy company and provider of solar storage and electric vehicle (EV) ...
Sound Pharmaceuticals is pleased to announce that it completed enrollment of its second Phase 3 open label study of SPI-1005 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results